Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Assets (2016 - 2026)

Insight Molecular Diagnostics' Assets history spans 7 years, with the latest figure at $25.8 million for Q4 2025.

  • On a quarterly basis, Assets fell 26.58% to $25.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.8 million, a 26.58% decrease, with the full-year FY2025 number at $25.8 million, down 26.58% from a year prior.
  • Assets hit $25.8 million in Q4 2025 for Insight Molecular Diagnostics, down from $43.9 million in the prior quarter.
  • Over the last five years, Assets for IMDX hit a ceiling of $177.4 million in Q2 2021 and a floor of $25.8 million in Q4 2025.
  • Historically, Assets has averaged $98.4 million across 5 years, with a median of $82.2 million in 2023.
  • Biggest five-year swings in Assets: surged 191.37% in 2021 and later crashed 53.16% in 2024.
  • Tracing IMDX's Assets over 5 years: stood at $159.6 million in 2021, then plummeted by 37.27% to $100.1 million in 2022, then fell by 25.18% to $74.9 million in 2023, then crashed by 53.16% to $35.1 million in 2024, then decreased by 26.58% to $25.8 million in 2025.
  • Business Quant data shows Assets for IMDX at $25.8 million in Q4 2025, $43.9 million in Q3 2025, and $50.5 million in Q2 2025.